IntraBio Announces Publication of Pivotal Phase III Data with Levacetylleucine for Ataxia-Telangiectasia in The Lancet Neurology

Source Summary

AUSTIN, Texas--(BUSINESS WIRE)--IntraBio Inc. today announced that results from its pivotal Phase III clinical trial evaluating levacetylleucine for the treatment of Ataxia-Telangiectasia (A-T) have been published in The Lancet Neurology. The peer-reviewed publication, titled “Safety and efficacy of levacetylleucine in ataxia telangiectasia: a phase 3, randomised, double-blind, placebo-controlled crossover trial” reports findings from IntraBio’s pivotal randomized, double-blind placebo-controll